PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsFamitinib
Famitinib
Famitinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against platelet-derived growth factor receptor beta, vascular endothelial growth factor receptor 2, and mast/stem cell growth factor receptor Kit.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
62 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50311315
Non-small-cell lung carcinomaD00228916411
Triple negative breast neoplasmsD06472617310
Lung neoplasmsD008175HP_0100526C34.901528
Uterine cervical neoplasmsD002583HP_0030159213
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A112
Colorectal neoplasmsD015179112
AdenocarcinomaD00023011
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C806510
CarcinomaD002277C80.0256
Renal cell carcinomaD002292EFO_000037633
OsteosarcomaD0125161123
Nasopharyngeal carcinomaD000077274223
Small cell lung carcinomaD055752133
Pancreatic neoplasmsD010190EFO_0003860C2522
RecurrenceD01200822
Disease progressionD018450122
Nasopharyngeal neoplasmsD009303122
Show 14 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients33
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFamitinib
INNfamitinib
Description
Famitinib is a tyrosine kinase receptor inhibitor developed by Jiangsu Hengrui for a variety of cancers.
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Identifiers
PDB
CAS-ID1044040-56-3
RxCUI
ChEMBL IDCHEMBL1278146
ChEBI ID
PubChem CID16662431
DrugBankDB11741
UNII ID768FW21J3L (ChemIDplus, GSRS)
Target
Agency Approved
PDGFRB
PDGFRB
KDR
KDR
KIT
KIT
Organism
Homo sapiens
Gene name
PDGFRB
Gene synonyms
PDGFR, PDGFR1
NCBI Gene ID
Protein name
platelet-derived growth factor receptor beta
Protein synonyms
Activated tyrosine kinase PDGFRB, Beta platelet-derived growth factor receptor, Beta-type platelet-derived growth factor receptor, CD140 antigen-like family member B, CD140b, NDEL1-PDGFRB, PDGF-R-beta, PDGFR-1, PDGFR-beta, Platelet-derived growth factor receptor 1, platelet-derived growth factor receptor, beta polypeptide
Uniprot ID
Mouse ortholog
Pdgfrb (18596)
platelet-derived growth factor receptor beta (P05622)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 292 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use